Drugs / TIN816
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05996835 | Jan 2024 → Feb 2026 | acute kidney injury | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05524051 | Mar 2023 → Mar 2025 | acute kidney injury | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT05507437 | Nov 2022 → Apr 2024 | acute kidney injury | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIN816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507437 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human CD39 enzyme” NCT05507437 ↗ |
| Route | Intravenous | “Administered as an intravenous dose” NCT05507437 ↗ |